GlassScriptPhysician profile
Melanie Ransom
NPI 1629658810
$4,350.48
in general payments reported to CMS, 2019-2025
29 companies · $1,964 in 2025
The $1,964 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.62 · 2022: $434 · 2023: $726 · 2024: $1,183 · 2025: $1,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,613 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,613.47 |
| Education | $259.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,126.89 | 2022-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $880.88 | 2023-2025 | |
| Genentech USA, INC. | $466.73 | 2023-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $259.97 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $242.90 | 2022-2025 | Dupixent |
| Optinose US, INC. | $203.23 | 2024-2025 | |
| Glaxosmithkline, LLC. | $158.49 | 2021-2025 | Nucala |
| Amgen INC. | $140.08 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $128.55 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $123.50 | 2025 | Neffy |
| Grifols USA, LLC | $92.42 | 2024-2025 | Xembify, Prolastin-C Liquid |
| Abbvie INC. | $83.31 | 2022-2025 | |
| Kaleo, INC. | $70.75 | 2021-2024 | Auvi-Q |
| Csl Behring | $41.42 | 2023-2025 | Haegarda |
| Lilly USA, LLC | $36.67 | 2025 | Ebglyss |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $36.60 | 2022-2025 | Opzelura |
| Biocryst US Sales Co., LLC | $31.42 | 2024-2025 | Orladeyo |
| Hikma Pharmaceuticals USA | $31.41 | 2025 | Ryaltris |
| Bio Products Laboratory USA, INC. | $29.86 | 2023 | Gammaplex, Coagadex |
| Pharming Healthcare, INC. | $29.65 | 2022-2024 | Ruconest |
| Covis Pharma Gmbh | $18.42 | 2022 | |
| Azurity Pharmaceuticals, INC. | $18.04 | 2025 | Alvesco |
| Ionis Pharmaceuticals, INC. | $17.70 | 2025 | Dawnzera |
| Arcutis Biotherapeutics, INC. | $16.97 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $14.51 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.62 | 2023 | Airduo Digihaler |
| Aimmune Therapeutics, INC. | $13.26 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.87 | 2022 | |
| Organon LLC | $10.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Ransom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.